Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra in Dermatomyositis
NCT02271165Phase 1Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of polyvalent human immunoglobulin in dermatomyositis (DM) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Change in strength based on MRC sumscores at 28 weeks. Started Nov 2014; status: terminated.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02271165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271165.